Genital Powder Use and Risk of Epithelial Ovarian Cancer in the Ovarian Cancer in Women of African Ancestry Consortium

Elisa V. Bandera & Holly R. Harris et al. · 2021-06-21

Abstract

Background:

Genital powder use is more common among African-American women; however, studies of genital powder use and ovarian cancer risk have been conducted predominantly in White populations, and histotype-specific analyses among African-American populations are limited.

Methods:

We used data from five studies in the Ovarian Cancer in Women of African Ancestry consortium. Participants included 620 African-American cases, 1,146 African-American controls, 2,800 White cases, and 6,735 White controls who answered questions on genital powder use prior to 2014. The association between genital powder use and ovarian cancer risk by race was estimated using logistic regression.

Results:

The prevalence of ever genital powder use for cases was 35.8% among African-American women and 29.5% among White women. Ever use of genital powder was associated with higher odds of ovarian cancer among African-American women [OR = 1.22; 95% confidence interval (CI) = 0.97–1.53] and White women (OR = 1.36; 95% CI = 1.19–1.57). In African-American women, the positive association with risk was more pronounced among high-grade serous tumors (OR = 1.31; 95% CI = 1.01–1.71) than with all other histotypes (OR = 1.05; 95% CI = 0.75–1.47). In White women, a significant association was observed irrespective of histotype (OR = 1.33; 95% CI = 1.12–1.56 and OR = 1.38; 95% CI = 1.15–1.66, respectively).

Conclusions:

While genital powder use was more prevalent among African-American women, the associations between genital powder use and ovarian cancer risk were similar across race and did not materially vary by histotype.

Impact:

This is one of the largest studies to date to compare the associations between genital powder use and ovarian cancer risk, overall and by histotype, between African-American and White women.

Funding
Collaborative Genetic Study of Ovarian Cancer RiskCLC NIH HHS Grant 75N90021D00002A Follow-up Study for Causes of Illness in Black WomenCancer Research Training and Education CoordinationNHLBI NIH HHS Grant HHSN268201600004CThe Molecular Epidemiology Of Ovarian CancerORFDO NIH HHS Grant 75N99021D00002An assessment of whether aspirin and/or vitamin D improves breast cancer outcomes in Black women and the modifying effect of genetic variantsWOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A2Women's Health Initiative Cancer Survivor CohortNHLBI NIH HHS Grant HHSN268201600002CA Follow-up Study for Causes of Cancer in Black WomenNHLBI NIH HHS Grant HHSN268201600018CA Follow-up Study for Causes of Cancer in Black WomenNHLBI NIH HHS Grant HHSN268201600003CNICHD NIH HHS Grant 75N94021D00002NHLBI NIH HHS Grant HHSN268201600001CExploring factors related to racial disparities in ovarian cancer incidence and survival: the OCWAA consortiumNIH HHS Grant 75N98021D00002Hormone Therapy and Risk of Ovarian CancerEpidemiology of Ovarian Cancer in African-American WomenExploring factors related to racial disparities in ovarian cancer incidence and survival: the OCWAA consortiumEpidemiology of Ovarian Cancer in African-American WomenA Follow-up Study for Causes of Illness in Black WomenA Follow-up Study for Causes of Cancer in Black WomenA Follow-up Study for Causes of Cancer in Black WomenNIH FundingNational Cancer Institute (NCI) Grant R01-CA61093Methylation Suicide in Cancer (PQ10)NCI Grant R01-CA58598Leadership, Planning and EvaluationCalifornia Cancer Research Program Grant 2II0200The Molecular Epidemiology Of Ovarian CancerNational Heart, Lung, and Blood Grant HHSN268201600018CNational Heart, Lung, and Blood Grant HHSN268201600001CNational Heart, Lung, and Blood Grant HHSN268201600002CNational Heart, Lung, and Blood Grant HHSN268201600003CNational Heart, Lung, and Blood Grant HHSN268201600004CNational Heart, Lung, and Blood Grant UM1-CA173642-05National Heart, Lung, and Blood Grant NHLBI-CSB-WH-2016-01-CMNational Heart, Lung, and Blood Grant NHLBI-75N92021D00002

NCI NIH HHS

R01 CA058598

NCI NIH HHS

R01 CA058420

NCI NIH HHS

P30 CA014089

NCI NIH HHS

R01 CA076016

NCI NIH HHS

K01 CA212056

NCI NIH HHS

UM1 CA173642

NCI NIH HHS

U01 CA164974

NCI NIH HHS

UM1 CA164974

NCI NIH HHS

R01 CA207260

NCI NIH HHS

P01 CA017054

NCI NIH HHS

R01 CA142081

NIH

R01-CA207260

NCI

R01-CA142081

NIH

R01-CA058420

NIH

UM1-CA164974

NIH

U01-CA164974

NCI

R01-CA17054

Cancer Center Core

P30-CA014089

NCI

R01-CA076016